The Effect of Docetaxel on Retinal Pigment Epithelial Cells

Overview

Journal Toxicol Rep

Date 2022 Apr 18

PMID 35433274

Authors

Jialin Li

Xiao Liu

Qiaohui Yang

Jian Huang

Wang Zhou

Zhirong Tan

Zhuo Li

Di Zhou

Affiliations

Soon will be listed here.

Abstract

Docetaxel (DTX) is a highly effective anti-tumor drug frequently used in clinical practice. Previous reports indicated that complications after DTX therapy could be related to retinal pigment epithelial (RPE) cell dysfunction, although no direct reports of this relationship have been published. In this study, human embryonic stem cell-derived RPE (hESC-RPE) cells were used to explore the effects of DTX on their morphology, viability, apoptosis, proliferation, and cell cycle. We also searched for DTX residue in these cells. DTX had a time- and concentration-dependent inhibitory effect on hESC-RPE cell viability, and the cells only survived after 24 h of stimulation with 0.1 mg/mL of DTX. Following drug withdrawal, the cell morphology continued to change, and hESC-RPE cell damage was observed. High-performance liquid chromatography/mass spectrometry showed that some unmetabolized DTX remained in hESC-RPE cells after the 48 and 120 h DTX treatments. Flow cytometry and immunofluorescence revealed that DTX significantly enhanced apoptosis, and the Cell Counting Kit-8 assay and flow cytometry indicated that DTX inhibited cell proliferation and blocked the cell cycle. These results suggest that DTX has a direct cytotoxic effect on hESC-RPE cells. Thus, RPE cell damage after DTX treatment may present an important safety problem that could potentially limit the application of this drug in clinical practice. The findings of this study suggest that clinicians should weigh the benefits of DTX versus the risks of ocular adverse reactions rationally. Timely diagnostic evaluation and drug withdrawal will be conducive to the recovery of patients' visual acuity.

References

Tababat-Khani P, Berglund L, Agardh C, Gomez M, Agardh E . Photocoagulation of human retinal pigment epithelial cells in vitro: evaluation of necrosis, apoptosis, cell migration, cell proliferation and expression of tissue repairing and cytoprotective genes. PLoS One. 2013; 8(8):e70465. PMC: 3731268. DOI: 10.1371/journal.pone.0070465. View

Yokoe T, Fukada I, Kobayashi K, Shibayama T, Miyagi Y, Yoshida A . Cystoid Macular Edema during Treatment with Paclitaxel and Bevacizumab in a Patient with Metastatic Breast Cancer: A Case Report and Literature Review. Case Rep Oncol. 2017; 10(2):605-612. PMC: 5567006. DOI: 10.1159/000477897. View

Skolnick C, Doughman D . Erosive conjunctivitis and punctal stenosis secondary to docetaxel (taxotere). Eye Contact Lens. 2003; 29(2):134-5. DOI: 10.1097/01.ICL.0000062464.79558.5A. View

Albany C, Sonpavde G . Docetaxel for the treatment of bladder cancer. Expert Opin Investig Drugs. 2015; 24(12):1657-64. DOI: 10.1517/13543784.2015.1109626. View

Wu W, Zeng Y, Li Z, Li Q, Xu H, Yin Z . Features specific to retinal pigment epithelium cells derived from three-dimensional human embryonic stem cell cultures - a new donor for cell therapy. Oncotarget. 2016; 7(16):22819-33. PMC: 5008403. DOI: 10.18632/oncotarget.8185. View

Bisacchi D, Benelli R, Vanzetto C, Ferrari N, Tosetti F, Albini A . Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives. Cancer Detect Prev. 2003; 27(3):229-38. DOI: 10.1016/s0361-090x(03)00030-8. View

Hortobagyi G . Recent progress in the clinical development of docetaxel (Taxotere). Semin Oncol. 1999; 26(3 Suppl 9):32-6. View

Johnson M . Etiology and treatment of macular edema. Am J Ophthalmol. 2008; 147(1):11-21.e1. DOI: 10.1016/j.ajo.2008.07.024. View

Schwartz S, Hubschman J, Heilwell G, Franco-Cardenas V, Pan C, Ostrick R . Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012; 379(9817):713-20. DOI: 10.1016/S0140-6736(12)60028-2. View

10.

Al-Zamil W, Yassin S . Recent developments in age-related macular degeneration: a review. Clin Interv Aging. 2017; 12:1313-1330. PMC: 5573066. DOI: 10.2147/CIA.S143508. View

11.

Elhusseiny A, Relhan N, Smiddy W . Docetaxel-induced maculopathy possibly potentiated by concurrent hydroxychloroquine use. Am J Ophthalmol Case Rep. 2019; 16:100560. PMC: 6804700. DOI: 10.1016/j.ajoc.2019.100560. View

12.

Esmaeli B, Ahmadi M, Rivera E, Valero V, Hutto T, Jackson D . Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol. 2002; 120(9):1180-2. View

13.

Banerjee A, Das D, Paul R, Roy S, Das U, Saha S . Mechanistic study of attenuation of monosodium glutamate mixed high lipid diet induced systemic damage in rats by Coccinia grandis. Sci Rep. 2020; 10(1):15443. PMC: 7508805. DOI: 10.1038/s41598-020-72076-6. View

14.

Han T, Shang D, Tian Y . Docetaxel enhances apoptosis and G2/M cell cycle arrest by suppressing mitogen-activated protein kinase signaling in human renal clear cell carcinoma. Genet Mol Res. 2016; 15(1). DOI: 10.4238/gmr.15017321. View

15.

Hecquet C, Lefevre G, Valtink M, Engelmann K, Mascarelli F . cAMP inhibits the proliferation of retinal pigmented epithelial cells through the inhibition of ERK1/2 in a PKA-independent manner. Oncogene. 2002; 21(39):6101-12. DOI: 10.1038/sj.onc.1205765. View

16.

Valeshabad A, Mieler W, Setlur V, Thomas M, Shahidi M . Posterior segment toxicity after gemcitabine and docetaxel chemotherapy. Optom Vis Sci. 2015; 92(5):e110-3. PMC: 4409528. DOI: 10.1097/OPX.0000000000000571. View

17.

Zeng Y, Yao X, Liu X, He X, Li L, Liu X . Anti-angiogenesis triggers exosomes release from endothelial cells to promote tumor vasculogenesis. J Extracell Vesicles. 2019; 8(1):1629865. PMC: 6586113. DOI: 10.1080/20013078.2019.1629865. View

18.

Seguin C, Kovacevich N, Voutsadakis I . Docetaxel-associated myalgia-arthralgia syndrome in patients with breast cancer. Breast Cancer (Dove Med Press). 2017; 9:39-44. PMC: 5271389. DOI: 10.2147/BCTT.S124646. View

19.

Banerjee A, Das D, Paul R, Roy S, Bhattacharjee A, Prasad S . Altered composition of high-lipid diet may generate reactive oxygen species by disturbing the balance of antioxidant and free radicals. J Basic Clin Physiol Pharmacol. 2020; 31(3). DOI: 10.1515/jbcpp-2019-0141. View

20.

Hartong D, Berson E, Dryja T . Retinitis pigmentosa. Lancet. 2006; 368(9549):1795-809. DOI: 10.1016/S0140-6736(06)69740-7. View